Analysis of defective protein ubiquitylation associated to adriamycin resistant cells

References

• Ciechanover A, Stanhill A. The complexity of recognition of ubiquitinated substrates by the 26S proteasome. Biochimica et biophysica acta. 2014;1843:86–96. doi:10.1016/j.bbamcr.2013.07.007. PMID:23872423.
   PubMed Web of Science ®Google Scholar
• Bassermann F, Eichner R, Pagano M. The ubiquitin proteasome system – implications for cell cycle control and the targeted treatment of cancer. Biochimica et biophysica acta. 2014;1843:150–162. doi:10.1016/j.bbamcr.2013.02.028. PMID:23466868.
   PubMed Web of Science ®Google Scholar
• Clague MJ, Heride C, Urbe S. The demographics of the ubiquitin system. Trends Cell Biol. 2015;25:417–426. doi:10.1016/j.tcb.2015.03.002. PMID:25906909.
   PubMed Web of Science ®Google Scholar
• Walczak H, Iwai K, Dikic I. Generation and physiological roles of linear ubiquitin chains. BMC Biol. 2012;10:23. doi:10.1186/1741-7007-10-23. PMID:22420778.
   PubMed Web of Science ®Google Scholar
• Heideker J, Wertz IE. DUBs, the regulation of cell identity and disease. Biochem J. 2015;465:1–26. doi:10.1042/BJ20140496. PMID:25631680.
   PubMed Web of Science ®Google Scholar
• Husnjak K, Dikic I. Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. Annu Rev Biochem. 2012;81:291–322. doi:10.1146/annurev-biochem-051810-094654. PMID:22482907.
   PubMed Web of Science ®Google Scholar
• Erpapazoglou Z, Walker O, Haguenauer-Tsapis R. Versatile roles of k63-linked ubiquitin chains in trafficking. Cells. 2014;3:1027–1088. doi:10.3390/cells3041027. PMID:25396681.
   PubMedGoogle Scholar
• Xolalpa W, Perez-Galan P, Rodriguez MS, Roue G. Targeting the ubiquitin proteasome system: beyond proteasome inhibition. Curr Pharm Des. 2013;19:4053–4093. doi:10.2174/1381612811319220014. PMID:23181575.
   PubMed Web of Science ®Google Scholar
• Mata-Cantero L, Lobato-Gil S, Aillet F, Lang VR MS. The ubiquitin-proteasome system (UPS) as a cancer drug target: emerging mechanisms and therapeutics. Stress Response Pathways in Cancer. From Molecular Targets to Novel Therapeutics: Springer, Dordrecht,. 2015.
   Google Scholar
• Gallo LH, Ko J, Donoghue DJ. The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle. 2017;16:634–648. doi:10.1080/15384101.2017.1288326. PMID:28166483.
   PubMed Web of Science ®Google Scholar
• Liu J, Zheng H, Tang M, Ryu YC, Wang X. A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am J Physiol Heart Circ Physiol. 2008;295:H2541–H2550. doi:10.1152/ajpheart.01052.2008. PMID:18978187.
   PubMed Web of Science ®Google Scholar
• Ranek MJ, Wang X. Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy. Curr Hypertens Rep. 2009;11:389–395. doi:10.1007/s11906-009-0068-8. PMID:19895749.
   PubMed Web of Science ®Google Scholar
• Serna S, Xolalpa W, Lang V, Aillet F, England P, Reichardt N, Rodriguez MS. Efficient monitoring of protein ubiquitylation levels using TUBEs-based microarrays. FEBS Lett. 2016;590:2748–2756. doi:10.1002/1873-3468.12289. PMID:27410252.
   PubMed Web of Science ®Google Scholar
• Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, England P, Rodriguez MS. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep. 2009;10:1250–1258. doi:10.1038/embor.2009.192. PMID:19798103.
   PubMed Web of Science ®Google Scholar
• Hjerpe R, Rodriguez MS. Efficient approaches for characterizing ubiquitinated proteins. Biochem Soc Trans. 2008;36:823–827. doi:10.1042/BST0360823. PMID:18793144.
   PubMed Web of Science ®Google Scholar
• Aillet F, Lopitz-Otsoa F, Hjerpe R, Torres-Ramos M, Lang V, Rodriguez MS. Isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. Methods Mol Biol. 2012;832:173–183. doi:10.1007/978-1-61779-474-2_12. PMID:22350885.
   PubMedGoogle Scholar
• Shi Y, Chan DW, Jung SY, Malovannaya A, Wang Y, Qin J. A data set of human endogenous protein ubiquitination sites. Molecular & cellular proteomics: MCP. 2011;10:M110 002089. doi:10.1074/mcp.M110.002089.
   PubMed Web of Science ®Google Scholar
• Lopitz-Otsoa F, Rodriguez-Suarez E, Aillet F, Casado-Vela J, Lang V, Matthiesen R, Elortza F, Rodriguez MS. Integrative analysis of the ubiquitin proteome isolated using Tandem Ubiquitin Binding Entities (TUBEs). J Proteomics. 2012;75:2998–3014. doi:10.1016/j.jprot.2011.12.001. PMID:22178446.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Saeki Y, Murakami A, Kawawaki J, Tsuchiya H, Yoshihara H, Shindo M, Tanaka K. A comprehensive method for detecting ubiquitinated substrates using TR-TUBE. Proc Natl Acad Sci U S A. 2015;112:4630–4635. doi:10.1073/pnas.1422313112. PMID:25827227.
   PubMed Web of Science ®Google Scholar
• Eisenberg-Lerner A, Ciechanover A, Merbl Y. Post-translational modification profiling – A novel tool for mapping the protein modification landscape in cancer. Exp Biol Med. 2016;241:1475–1482. doi:10.1177/1535370216651732. PMID:27229346.
   PubMed Web of Science ®Google Scholar
• Altun M, Kramer HB, Willems LI, McDermott JL, Leach CA, Goldenberg SJ, Kumar KG, Konietzny R, Fischer R, Kogan E, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol. 2011;18:1401–1412. doi:10.1016/j.chembiol.2011.08.018.
   PubMed Web of Science ®Google Scholar
• Seiberlich V, Goldbaum O, Zhukareva V, Richter-Landsberg C. The small molecule inhibitor PR-619 of deubiquitinating enzymes affects the microtubule network and causes protein aggregate formation in neural cells: implications for neurodegenerative diseases. Biochimica et biophysica acta. 2012;1823:2057–2068. doi:10.1016/j.bbamcr.2012.04.011. PMID:22565157.
   PubMed Web of Science ®Google Scholar
• Sane S, Rezvani K. Essential Roles of E3 Ubiquitin Ligases in p53 Regulation. International journal of molecular sciences. 2017;18. doi:10.3390/ijms18020442. PMID:28218667.
   PubMed Web of Science ®Google Scholar
• Armstrong SR, Wu H, Wang B, Abuetabh Y, Sergi C, Leng RP. The Regulation of Tumor Suppressor p63 by the Ubiquitin-Proteasome System. Int J Mol Sci. 2016;17(12):2041. doi:10.3390/ijms17122041. PMID:27929429.
   PubMed Web of Science ®Google Scholar
• Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, Torres-Ramos M, Farras R, Hay RT, Rodriguez MS. Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation. The international journal of biochemistry & cell biology. 2010;42:725–735. doi:10.1016/j.biocel.2010.01.010.
   PubMed Web of Science ®Google Scholar
• Lang V, Pallara C, Zabala A, Lobato-Gil S, Lopitz-Otsoa F, Farras R, Hjerpe R, Torres-Ramos M, Zabaleta L, Blattner C, et al. Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity. Mol Oncol. 2014;8:1026–1042. doi:10.1016/j.molonc.2014.04.002. PMID:24816189.
   PubMed Web of Science ®Google Scholar
• Gehrmann ML, Fenselau C, Hathout Y. Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. Journal of proteome research. 2004;3:403–409. doi:10.1021/pr0340577. PMID:15253420.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liang S, Lian X, Liu L, Zhao S, Xuan Q, Guo L, Liu H, Yang Y, Dong T, et al. Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis. Sci Rep. 2015;5:9301. doi:10.1038/srep09301. PMID:25818003.
   PubMed Web of Science ®Google Scholar
• Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE. Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochemical pharmacology 1987;36:793–796. doi:10.1016/0006-2952(87)90164-X. PMID:3032195.
   PubMed Web of Science ®Google Scholar
• Demasi M, Simoes V, Bonatto D. Cross-talk between redox regulation and the ubiquitin-proteasome system in mammalian cell differentiation. Biochimica et biophysica acta. 2015;1850:1594–1606. doi:10.1016/j.bbagen.2014.10.031. PMID:25450485.
   PubMed Web of Science ®Google Scholar
• Bossis G, Sarry JE, Kifagi C, Ristic M, Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, et al. The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs. Cell Rep. 2014;7:1815–1823. doi:10.1016/j.celrep.2014.05.016. PMID:24910433.
   PubMed Web of Science ®Google Scholar
• Davies R, Budworth J, Riley J, Snowden R, Gescher A, Gant TW. Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. British journal of cancer 1996;73:307–315. doi:10.1038/bjc.1996.54. PMID:8562335.
   PubMed Web of Science ®Google Scholar
• Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986;261:15544–15549. PMID:3782078.
   PubMed Web of Science ®Google Scholar
• Januchowski R, Sterzynska K, Zaorska K, Sosinska P, Klejewski A, Brazert M, Nowicki M, Zabel M. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 2016;9:65. doi:10.1186/s13048-016-0278-z. PMID:27756418.
   PubMed Web of Science ®Google Scholar
• Aillet F, Lopitz-Otsoa F, Egana I, Hjerpe R, Fraser P, Hay RT, Rodriguez MS, Lang V. Heterologous SUMO-2/3-ubiquitin chains optimize IkappaBalpha degradation and NF-kappaB activity. PloS One. 2012;7:e51672. doi:10.1371/journal.pone.0051672. PMID:23284737.
   PubMed Web of Science ®Google Scholar